Institute for OneWorld Health Receives Grant To Lay Foundation for Next Steps in Control of Deadly Infectious Disease

SAN FRANCISCO -- The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., today announced that it has received a grant of nearly US$10 million from the Bill & Melinda Gates Foundation to continue advancing its promising drug for visceral leishmaniasis (VL), paromomycin, through the approval and post-approval process.  Specifically, the company will seek regulatory approval in India this year, execute a post-approval Phase IV study, and complete a clinical trial of shorter duration of administration to optimize the use of paromomycin. The grant will also support the company’s work with partners to manufacture paromomycin at an affordable cost.

To view the full press release, visit The Institute for OneWorld Health's Web site.

###

The Institute for OneWorld Health, the first U.S. nonprofit pharmaceutical company, develops new, affordable medicines for infectious diseases that disproportionately affect people in the developing world, including visceral leishmaniasis, malaria, diarrhea and Chagas disease. OneWorld Health applies its entrepreneurial business model with a staff of experienced pharmaceutical scientists that identifies promising leads and drives development from pre-clinical studies to clinical trials through regulatory approval. The Institute for OneWorld Health, headquartered in San Francisco, Calif., is a tax-exempt 501(c) (3) U.S. corporation.